Prostate-specific antigen (PSA) is a well-characterized human prostate
-specific glycoprotein. PSA has been shown to be the most effective im
munohistologic marker for prostate cancer, as well as the most useful
serologic test in staging and monitoring prostate cancer and in early
detection of recurrent disease. The greatest clinical value of PSA is
as an aid for early detection of prostate cancer. Recent studies have
indicated that PSA-based screening of the older population for organ-c
onfined early-stage prostate cancer is an acceptable, practical, and r
eliable modality. The accuracy of PSA screening is within the same ran
ge as the mammogram. The cost-effectiveness of PSA is comparable to ot
her cancer screening tests. Although the increase in the patient's sur
vival due to PSA-based detection of early prostate cancer remains to b
e documented, it is generally agreed that the PSA test along with digi
tal rectal examination (DRE) should be included in the annual physical
examination for men 50 years of age or older. High-risk men are urged
to commence at age 40. Asymptomatic men who have both a negative DRE
and normal PSA blood test need only to continue an annual DRE and PSA
check-up. Men who have a negative DRE and elevated PSA, and all those
who have a suspicious DRE regardless of PSA results, should undergo fu
rther diagnostic workup, such as transrectal ultrasonography with biop
sy of visible lesions. The cure rate is high with timely treatment, wh
en prostate cancer is detected while still confined to the prostate. (
C) 1994 Wiley-Liss, Inc.